Literature DB >> 29572346

CD83 in Hodgkin lymphoma.

Ralf Küppers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29572346      PMCID： PMC5865444          DOI： 10.3324/haematol.2018.188870

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera.

Authors:  B D Hock; M Kato; J L McKenzie; D N Hart
Journal:  Int Immunol       Date:  2001-07       Impact factor: 4.823

2.  Hodgkin's cells express CD83, a dendritic cell lineage associated antigen.

Authors:  U R Sorg; T M Morse; W N Patton; B D Hock; H B Angus; B A Robinson; B M Colls; D N Hart
Journal:  Pathology       Date:  1997-08       Impact factor: 5.306

Review 3.  CD83: a regulatory molecule of the immune system with great potential for therapeutic application.

Authors:  Yoko Fujimoto; Thomas F Tedder
Journal:  J Med Dent Sci       Date:  2006-06

Review 4.  Hodgkin lymphoma.

Authors:  Ralf Küppers; Andreas Engert; Martin-Leo Hansmann
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

5.  Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas.

Authors:  Gabriel D Victora; David Dominguez-Sola; Antony B Holmes; Stephanie Deroubaix; Riccardo Dalla-Favera; Michel C Nussenzweig
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

6.  Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma.

Authors:  Frederik Wein; Marc A Weniger; Benedikt Höing; Judith Arnolds; Andreas Hüttmann; Martin-Leo Hansmann; Sylvia Hartmann; Ralf Küppers
Journal:  Cancer Immunol Res       Date:  2017-10-25       Impact factor: 11.151

7.  Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.

Authors:  Ines Schwering; Andreas Bräuninger; Ulf Klein; Berit Jungnickel; Marianne Tinguely; Volker Diehl; Martin-Leo Hansmann; Riccardo Dalla-Favera; Klaus Rajewsky; Ralf Küppers
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

8.  Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.

Authors:  Enrico Tiacci; Claudia Döring; Verena Brune; Carel J M van Noesel; Wolfram Klapper; Gunhild Mechtersheimer; Brunangelo Falini; Ralf Küppers; Martin-Leo Hansmann
Journal:  Blood       Date:  2012-09-05       Impact factor: 22.113

9.  CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

Authors:  Ziduo Li; Xinsheng Ju; Kenneth Lee; Candice Clarke; Jennifer L Hsu; Edward Abadir; Christian E Bryant; Suzanne Pears; Neroli Sunderland; Scott Heffernan; Annemarie Hennessy; Tsun-Ho Lo; Geoffrey A Pietersz; Fiona Kupresanin; Phillip D Fromm; Pablo A Silveira; Con Tsonis; Wendy A Cooper; Ilona Cunningham; Christina Brown; Georgina J Clark; Derek N J Hart
Journal:  Haematologica       Date:  2018-01-19       Impact factor: 9.941

Review 10.  Regulation of immune reactivity by intercellular transfer.

Authors:  Maxime Dhainaut; Muriel Moser
Journal:  Front Immunol       Date:  2014-03-28       Impact factor: 7.561
View more
  2 in total

Review 1.  CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.

Authors:  Ziduo Li; Xinsheng Ju; Pablo A Silveira; Edward Abadir; Wei-Hsun Hsu; Derek N J Hart; Georgina J Clark
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

2.  Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.

Authors:  Adrián Mosquera Orgueira; Roi Ferreiro Ferro; José Ángel Díaz Arias; Carlos Aliste Santos; Beatriz Antelo Rodríguez; Laura Bao Pérez; Natalia Alonso Vence; Ággeles Bendaña López; Aitor Abuin Blanco; Paula Melero Valentín; And Res Peleteiro Raindo; Miguel Cid López; Manuel Mateo Pérez Encinas; Marta Sonia González Pérez; Máximo Francisco Fraga Rodríguez; José Luis Bello López
Journal:  PLoS One       Date:  2021-05-04       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.